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Conditional JAG1 Mutation Shows the Developing Heart Is More Sensitive
Than Developing Liver to JAG1 Dosage
Fengmin Lu,* Jennifer J. D. Morrissette,* and Nancy B. Spinner
Division of Human Genetics and Molecular Biology, Department of Pediatrics and Clinical Laboratories, The Children’s Hospital of
Philadelphia, Philadelphia
Mutations of Jagged 1 (JAG1), a ligand in the Notch signaling pathway, cause Alagille syndrome (AGS). AGS is
an autosomal dominant, multisystem disorder with variable expressivity, characterized by bile duct paucity and
resultant liver disease in combination with cardiac, ocular, skeletal, and facial findings. JAG1 mutations in AGS
include gene deletions and protein truncating, splicing, and missense mutations, suggesting that haploinsufficiency
is the mechanism of disease causation. With limited exceptions, there is no genotype-phenotype correlation. We
have studied a JAG1 missense mutation (JAG1-G274D) that was previously identified in 13 individuals from an
extended family with cardiac defects of the type seen in patients with AGS (e.g., peripheral pulmonic stenosis and
tetralogy of Fallot) in the absence of liver dysfunction. Our data indicate that this mutation is “leaky.” Two
populations of proteins are produced from this allele. One population is abnormally glycosylated and is retained
intracellularly rather than being transported to the cell surface. A second population is normally glycosylated and
is transported to the cell surface, where it is able to signal to the Notch receptor. The JAG1-G274D protein is
temperature sensitive, with more abnormally glycosylated (and nonfunctional) molecules produced at higher tem-
peratures. Carriers of this mutation therefore have 150% but !100% of the normal concentration of JAG1molecules
on the cell surface. The cardiac-specific phenotype associated with this mutation suggests that the developing heart
is more sensitive than the developing liver to decreased dosage of JAG1.
Alagille syndrome (AGS [MIM 118450]) is an autoso-
mal dominant disorder, characterized by bile duct pau-
city (a reduction in the number of bile ducts seen on
liver biopsy) that leads to cholestasis (the obstruction of
biliary flow) in association with other clinical abnor-
malities. These include cardiac, musculoskeletal, ocular,
facial, and, less frequently, renal and neurodevelopmen-
tal abnormalities (Watson and Miller 1973; Alagille et
al. 1975, 1987). Cardiac defects most often involve the
pulmonary vasculature, but other structural defects can
be seen (Silberbach et al. 1994; Emerick et al. 1999;
Krantz et al. 1999). Other clinical findings include cleft-
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ing of the vertebral bodies (butterfly vertebrae) and pos-
terior embryotoxon (a defect of the anterior chamber of
the eye). Affected individuals may have characteristic
facial features, including a broad forehead, widely
spaced, deep-set eyes, and a pointed chin. The clinical
findings in AGS can be highly variable, even within the
same family (Shulman et al. 1984; Elmslie et al. 1995;
Emerick et al. 1999).
AGS is caused by mutations in Jagged 1 (JAG1 [MIM
601920]), a cell surface ligand for the Notch transmem-
brane receptors (Lindsell et al. 1995; Li et al. 1997; Oda
et al. 1997). The evolutionarily conserved Notch sig-
naling pathway functions to regulate cell fate decisions
during development (Artavanis-Tsakonas et al. 1999;
Kadesch et al. 2000). JAG1 mutations in patients with
AGS are distributed throughout the gene and include
protein truncating, splicing, and missense mutations, as
well as total gene deletions (Krantz et al. 1998; Crosnier
et al. 1999; Spinner et al. 2001). Since the same phe-
notypic features can be present in individuals with total
gene deletions, missense mutations, and protein-trun-
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cating mutations, we propose that haploinsufficiency for
JAG1 is one mechanism causing AGS.
Missense mutations have been found in patients with
AGS, although the mechanism by which they act is not
as clearly understood as that for gene deletions or trun-
cating mutations. We previously studied four JAG1 mis-
sense mutations (L37S, R184H, P163L, and P871R)
(Morrissette et al. 2001). JAG1-R184H has been iden-
tified in multiple patients with AGS; JAG1-L37S and
JAG1-P163L have been reported in single patients with
AGS; and P871R has been found in patients and un-
affected individuals, suggesting it is a polymorphism
(Spinner et al. 2001). Expression studies of JAG1-
R184H and JAG1-L37S demonstrated loss of Notch sig-
naling in two functional assays, whereas the other two
mutations (P163L and P871R) appeared to have no ef-
fect on activity (Morrissette et al. 2001). On the basis
of these data, we have hypothesized that P163L is a
polymorphism and that its identification in a patient
with AGS was fortuitous. Analysis of JAG1-R184H and
-L37S protein products revealed incomplete N-linked
glycosylation modifications. The mutant proteins were
not found on the cell surface; instead, they were found
to accumulate in the endoplasmic reticulum. These ex-
periments demonstrated that the R184H and L37S mu-
tations result in functional haploinsufficiency.
No genotype-phenotype correlation has been noted
among the mutations identified in patients with AGS to
date. Within families, the same JAG1 mutations have
been found to be associated with very different clinical
features, ranging from severe heart and liver disease to
very mild findings in a single organ (Watson and Miller
1973; LaBreque et al. 1982; Alagille et al. 1987; Krantz
et al. 1998). However, in a recent report, the first po-
tential example of a JAG1 mutation with a specific
phenotypic consequence was identified (Eldadah et al.
2001). A JAG1 missense mutation, JAG1-G274D, was
found to segregate with a cardiac-specific phenotype.
This mutation was found in 13 individuals within a mul-
tigeneration family with isolated cardiac disease. Al-
though some of these individuals were thought to have
facial features consistent with AGS, none of them had
a history of liver disease. Of 11 individuals who were
available for clinical study, 2 were affectedwith tetralogy
of Fallot, 6 had peripheral pulmonic stenosis, and 1 had
ventricular septal defect with aortic dextroposition. Two
individuals had no overt cardiac abnormalities; however,
one of the unaffected individuals was the mother of two
children with cardiac disease (tetralogy of Fallot and
pulmonic stenosis), suggesting she is an obligate carrier.
The JAG1-G274D mutation changes a highly conserved
glycine residue within the epidermal growth factor–like
repeats and has not been seen in any of the200 patients
with AGS who were studied or in the 80 population
control individuals (Li et al. 1997; Oda et al. 1997). The
limited manifestations of this mutation led us to hy-
pothesize that it might be different from the JAG1 mis-
sense mutations reported in patients with AGS. In the
present report, we describe the results of expression stud-
ies of the JAG1 missense mutation JAG1-G274D.
To study the expression of the JAG1 missense mu-
tation JAG1-G274D, the mutant was cloned into the
pBABE retroviral expression vector and was expressed
in NIH-3T3 cells (Morgenstern and Land 1990). The
JAG1-G274D mutant construct was made by site-
directed mutagenesis, using wild-type JAG1 as a tem-
plate, as described elsewhere (Morrissette et al. 2001).
Wild-type JAG1 and JAG1 that contains missense mu-
tations (L37S or G274D) were introduced intoNIH-3T3
cells, using the retroviral expression vector, pBABE-
puro, into which JAG1 or JAG1 mutant was cloned.
Western blot analysis of untreated lysates from the cells
expressing JAG1 and JAG1 mutants, using a polyclonal
antibody to the C-terminal region (H-114; Santa Cruz,
Inc.), revealed that the JAG1-L37S mutant protein has
a slightly lower mobility than wild-type JAG1. This dif-
ference was shown to be due to differences in posttran-
slational glycosylation (Morrissette et al. 2001). In con-
trast, the JAG1-G274D protein appeared as a doublet,
comigrating with both the wild-type and JAG1-L37S
bands, suggesting that more than one species of protein
is present (fig. 1). To begin to analyze posttranslational
modification of the JAG1-G274D protein, cell lysates
were subjected to western blot analysis before and after
treatment with endonuclease H (Endo H), which re-
moves high-mannose or hybrid N-linked carbohydrate
structures but cannot remove complex carbohydrates.
Wild-type JAG1 is Endo H resistant, presumably as a
result of its modification with complex carbohydrates.
The JAG1 mutants R184H and L37S, identified in pa-
tients with AGS, have been shown to be Endo H sen-
sitive. We hypothesize that they are not properly gly-
cosylated and are not properly targeted to the Golgi for
processing, and they are therefore retained intracellu-
larly rather than being trafficked to the cell surface.
(Morrissette et al. 2001).
Endo H treatment revealed different sensitivities for
wild-type JAG1, JAG1-L37S, and JAG1-G274D. As dis-
cussed above, wild-type JAG1 was resistant to Endo H,
and JAG1-L37S was sensitive to Endo H. JAG1-G274D
demonstrated two bands after Endo H treatment, in-
dicating both resistant and sensitive protein populations
(fig. 1). We hypothesized that these two populations dif-
fer in conformation, resulting in the correct processing
of a subset of the JAG1-G274D protein. The JAG1-
G274D-Endo H–resistant population is fully glycosy-
lated (with complex modifications, similar to wild-type
JAG1) and is targeted to the cell membrane, whereas
the sensitive fraction is incompletely glycosylated and
does not appear on the cell surface.
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Figure 1 Western blot analysis of cell lysates containing the JAG1-G274D protein. Comparison of lysates before and after treatment with
Endo H demonstrates two populations of proteins. NIH-3T3 cells expressing wild-type JAG1 or JAG1-L37S or JAG1-G274D JAG1 mutants
were grown at 37C overnight. Cell lysates were run on a 7.5% SDS polyacrylamide gel and transferred to a polyvinylidene difluoridemembrane
as described in the text. Western analysis was performed on cell lysates, using H114 (a JAG1 C-terminal antibody [Santa Cruz]) and were
visualized by chemiluminescence. Cell lysates were untreated (Endo H) or were treated (Endo H) for 60 min, demonstrating partial sensitivity
of JAG1-G274D to Endo H.
To determine if JAG1-G274D is localized to the cell
surface, we treated NIH-3T3 cells that express wild-type
or mutant JAG1 with the protease trypsin, such that only
proteins on the cell surface would be degraded. When
wild-type JAG1 was treated with trypsin, the full-length
product decreased, and lower-molecular-weight bands,
consistent with proteolytic products, appeared. Con-
versely, the mutant JAG1-L37S was insensitive to tryp-
sin, consistent with its absence from the cell surface (fig.
2A). We hypothesized that the two JAG1-G274D pro-
tein populations differ in conformation, with only one
of these populations reaching the cell surface. Therefore,
this JAG1 protein would be partially resistant to trypsin.
We further predicted that the JAG1-G274D protein
would be more stable at lower temperatures, as has been
demonstrated for other mutant proteins, such as cystic
fibrosis transmembrane conductance regulator (CFTR)
(Sharma et al. 2001). We assayed trypsin sensitivity of
JAG1-G274D at two different temperatures (33C and
39C) (fig. 2B). JAG1-G274D was partially sensitive to
trypsin at both temperatures, with some but not all of
the protein cleaved on trypsin treatment. When cells ex-
pressing JAG1-G274D and grown at 33C were ana-
lyzed by densitometry, the ratio of the two primary deg-
radation products (marked with an asterisk in fig. 2B)
to full-length JAG1 was 3.74. When cells were grown
at 39C, the ratio was 1.096. This is consistent with the
appearance of more protein at the cell surface—and
therefore with more degradation of JAG1-G274D—
when cells were grown at the lower temperature (33C).
These results were also consistent with immunofluoresc-
ence experiments, in which the cellular localization of
JAG1-G274D was studied after expression in NIH-3T3
cells (data not shown). These experiments demonstrated
that JAG1-G274D was both intracellular and on the cell
surface of cells grown at 39C (data not shown), whereas
cells grown at 33C demonstrated more protein on the
cell surface and transiting through the Golgi. No dif-
ference was observed in the subcellular localization of
wild-type JAG1 at either temperature.
To examine the activity of the JAG1-G274D mutant,
we assayed its ability to interact with Notch and to ac-
tivate a downstream promoter at 32C or 37C. JAG1
activity was analyzed using a transcriptional reporter
assay that detects Notch activation by JAG1. For these
studies, we used a reporter plasmid (4XwtCBFLUC) that
contained a luciferase construct cloned downstream of
a Notch-sensitive promoter (Hsieh et al 1996). Wild-
type JAG1 demonstrated a similar level of Notch acti-
vation at both 32C and 37C (fig. 3). JAG1-G274D
demonstrated ∼3.5-fold greater activity at 32C (∼59%
of wild type), compared with 37C (∼17% of wild type),
consistent with an increase in the stability of the mutant
protein due to a temperature-sensitive conformational
change ( , by independent sample t test). ThePp .004
activity of the AGS-associated mutant protein JAG1-
L37S, was slightly greater at 32C, but this difference
was not statistically significant ( ).Pp .14
The results presented here suggest that the JAG1 mis-
sense mutation JAG1-G274D is “leaky,” in that both
normal and abnormal protein species are produced. The
mutant allele produces a conformationally sensitive pro-
tein existing in two forms. One form is correctly mod-
ified posttranslationally, reaches the cell surface, and is
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Figure 2 Sensitivity of wild-type and mutant JAG1 to trypsin. A, Wild-type JAG1. Wild-type protein, expressed in NIH-3T3 cells grown
at 33C or 37C, is sensitive to mild trypsin treatment, consistent with its being expressed on the cell surface. JAG1-L37S expressed in NIH-
3T3 cells grown at 33C or 37C is not sensitive to trypsin, consistent with its absence from the cell surface. Arrows indicate degradation
products seen for wild-type JAG1. B, JAG1-G274D. Mutant protein, expressed in NIH-3T3 cells grown at 33C or 37C, is partially sensitive
to trypsin, although there is increased degradation at 33C, consistent with a higher proportion of protein being transported to the cell surface
at this temperature. For all experiments, cells were exposed to trypsin for 0 or 10 min, after which the trypsin was inactivated. The cells were
lysed in NP40 buffer and were analyzed by western blot. Asterisks indicate primary degradation products.
functionally normal. The second form is improperly
modified, does not reach the cell surface, and is therefore
not active. Temperature sensitivity has been demon-
strated in other mutant protein molecules that require
proper folding and posttranslational modification for
targeting to the cell membrane (Michalovitz et al. 1990;
Sharma et al. 2001).
This conditional mutant, JAG1-G274D, is associated
with a cardiac-specific phenotype, providing the first ex-
ample of a JAG1 genotype-phenotype correlation. Hap-
loinsufficiency for JAG1 is associated with the well-char-
acterized (but variably expressed) phenotype of AGS.
Previously studied JAG1 missense mutations associated
with the classic AGS phenotype displayed functional
haploinsufficiency, in that they were unable to reach the
cell surface, resulting in cell surface concentrations that
were 50% of wild-type levels. In contrast, individuals
with a JAG1-G274D allele have 150% but !100% of
wild-type concentrations. Because the phenotype of the
JAG1-G274D mutant appears to be cardiac specific—no
individuals with this mutation have been found to have
liver disease (Eldadah et al. 2001)—we hypothesize that
the developing heart requires a higher dosage of JAG1
for normal development, compared with the liver. Al-
ternatively, this mutation could involve differences in
posttranslational processing of JAG1 during develop-
ment of liver and cardiac cells.
Phenotypes have been shown to vary in many families
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Figure 3 Temperature-dependent Notch activation by JAG1-G274D. NIH-3T3 cells were maintained in Dulbecco’s modified Eaglemedium
with 10% fetal bovine serum. Cells were transfected with the Notch-responsive plasmid 4XwtCBF1Luc. Transfected cells were seeded with
NIH-3T3 cells expressing wild-type JAG1, JAG1-L37S, or JAG1-G274D and were incubated at either 32C or 37C for 72 h. Luciferase activity
was measured, and transfections were normalized for the amount of total cellular protein (Biorad) and were repeated in triplicate. Transcription
from 4XwtCBF1Luc was normalized to wild-type JAG1, having 100% activity at 37C. The mutant JAG1-L37S had very low activity, with
no significant difference between values at 32C or 37C ( ). JAG1-G274D demonstrates a threefold increase in Notch activation atPp .14
32C compared with 37C ( ), suggesting a conditional intermediate phenotype.Pp .004
segregating JAG1 mutations, suggesting the presence of
modifying factors. On the basis of the work presented
here, we hypothesize that polymorphisms in any of the
proteins that modulate JAG1-induced Notch signaling
might serve as modifiers of the AGS phenotype. JAG1
functions by binding to one of the Notch receptors, trig-
gering a ligand-induced proteolytic cleavage of the re-
ceptor, with nuclear localization of the intracellular por-
tion of the receptor. The Notch receptor fragment in the
nucleus then binds to other proteins to direct transcrip-
tion of Notch-responsive genes. Therefore, any of the
many proteins involved in Notch cleavage, nuclear trans-
location, or Notch-mediated transcription might serve
as potential modifiers of the AGS phenotype (Wein-
master 2000). Recent work has demonstrated that
Notch2 is a modifier for AGS features in the mouse
(McCright et al. 2002). Further studies will show
whether Notch2 is a modifier of JAG1 mutations in pa-
tients with AGS or isolated cardiac disease, as was seen
in the family with the JAG1-G274D mutation.
We have studied a single, unusual family with a car-
diac-specific phenotype associated with a JAG1missense
mutation. Although we recognize that it may be pre-
mature to draw conclusions from studies of a single mu-
tation, we feel that the evidence is compelling that this
mutation produces a higher proportion of functional
JAG1 protein and that individuals with this mutation
do not demonstrate liver disease, which is usually seen
in patients with AGS. We therefore propose that the
developing liver requires less JAG1 (150% but !100%
of normal levels) than the heart. Recently, another family
was described that had a JAG1 missense mutation
(C234Y) and congenital heart disease, hearing loss, and
posterior embryotoxon (Le Caignec et al. 2002). Studies
of this mutation are under way, and proof of our hy-
pothesis will depend on whether other families are iden-
tified that have the same or similar mutations.
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